Yamamoto Tomomaya, Hasegawa Tomoka, Fraitas Paulo Henrique Luiz de, Hongo Hiromi, Zhao Shen, Yamamoto Tsuneyuki, Nasoori Alireza, Abe Miki, Maruoka Haruhi, Kubota Keisuke, Morimoto Yasuhito, Haraguchi Mai, Shimizu Tomohiro, Takahata Masahiko, Iwasaki Norimasa, Li Minqi, Amizuka Norio
Developmental Biology of Hard Tissue, Graduate School of Dental Medicine, and Faculty of Dental Medicine, Hokkaido University.
Northern Army Medical Unit, Camp Makomanai, Japan Ground Self-Defense Forces.
Biomed Res. 2021;42(5):161-171. doi: 10.2220/biomedres.42.161.
Modeling, the changes of bone size and shape, often takes place at the developmental stages, whereas bone remodeling-replacing old bone with new bone-predominantly occurs in adults. Unlike bone remodeling, bone formation induced by modeling i.e., minimodeling (microscopic modeling in cancellous bone) is independent of osteoclastic bone resorption. Although recently-developed drugs for osteoporotic treatment could induce minimodeling-based bone formation in addition to remodeling-based bone formation, few reports have demonstrated the histological aspects of minimodeling-based bone formation. After administration of eldecalcitol or romosozumab, unlike teriparatide treatment, mature osteoblasts formed new bone by minimodeling, without developing thick preosteoblastic layers. The histological characteristics of minimodeling-based bone formation is quite different from remodeling, as it is not related to osteoclastic bone resorption, resulting in convex-shaped new bone and smooth cement lines called arrest lines. In this review, we will show histological properties of minimodeling-based bone formation by osteoporotic drugs.
骨大小和形状的改变建模通常发生在发育阶段，而骨重塑——用新骨替代旧骨——主要发生在成年人中。与骨重塑不同，建模诱导的骨形成，即微建模（松质骨中的微观建模）独立于破骨细胞性骨吸收。尽管最近开发的用于骨质疏松症治疗的药物除了能诱导基于重塑的骨形成外，还能诱导基于微建模的骨形成，但很少有报告展示基于微建模的骨形成的组织学特征。与特立帕肽治疗不同，给予 eldecalcitol 或 romosozumab 后，成熟成骨细胞通过微建模形成新骨，而不会形成厚厚的前成骨细胞层。基于微建模的骨形成的组织学特征与重塑有很大不同，因为它与破骨细胞性骨吸收无关，从而形成凸形新骨和称为休止线的光滑黏合线。在这篇综述中，我们将展示骨质疏松症药物诱导的基于微建模的骨形成的组织学特性。
